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rhabdomyosarcoma diagnostics
Aims: Subclassification of rhabdomyosarcoma (RMS)
has clinical relevance, as the two major subclasses
embryonal (ERMS) and alveolar (ARMS) rhabdomyo-
sarcoma differ greatly in terms of aggressiveness and
prognosis. However, histological analysis is not always
sufficient for an unequivocal subclassification of RMS.
Furthermore, clinical presentation of ARMS has been
reported to mimic other tumour types, specifically
lymphoma. The aim was to determine the role of four
biomarkers in the diagnosis of rhabdomyosarcoma.
Methods and results: Recently, we identified four poten-
tial biomarkers to subclassify RMS with high sensitivity
and specificity. These included epidermal growth factor
receptor (EGFR) and fibrillin-2 as markers for ERMS,
and AP2b and P-cadherin as markers for translocation-
positive ARMS. Here, we further validate the potential
of these four markers in a second, independent patient
cohort by immunohistochemistry on 80 sections of
RMS biopsy specimens as well as a tissue microarray
representing 18 different additional tumour types,
including seven lymphomas. The combination of EGFR
and fibrillin-2 was able to detect ERMS with a specificity
of 76% and sensitivity of 90%. The combination of
AP2b and P-cadherin detected ARMS with a specificity
of 97% and sensitivity of 90%, data very similar to our
previous study. Furthermore, all lymphomas were
clearly negative for AP2b and P-cadherin.
Conclusions: These four biomarkers are suitable for
clinical implementation in the future diagnosis of RMS.
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Introduction
Rhabdomyosarcoma (RMS) is the most common soft
tissue tumour in childhood, with an overall incidence
of 5–8% of childhood tumours. It falls into the class of
small round blue cell tumors, is thought to derive from
myogenic precursor cells and thus can occur at various
locations in the body.
Histologically, two main subtypes of rhabdomyo-
sarcoma are distinguished with significant relevance
as regards clinical outcome and survival. The
more common embryonal rhabdomyosarcoma (ERMS)
shows better response to established treatment regi-
mens, reflected by an event-free 5-year survival rate of
70% compared with only 45% in children affected by
alveolar rhabdomyosarcoma (ARMS).1 This difference
in treatment options and prognosis emphasizes the
importance of a clear distinction between ERMS and
ARMS upon diagnosing a child with RMS.
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Unfortunately, histological discrimination between
the different subtypes can sometimes be difficult.
Furthermore, ARMS can present as widespread disease
with an occult primary site mimicking other neoplasms
such as leukaemia,2,3 or lymphoma4,5 rendering the
diagnostic process even more challenging. Therefore,
other methods have been designed to assist in the
diagnosis of RMS. Apart from molecular methods such
as polymerase chain reaction or fluorescence in situ
hybridization to detect specific translocations in ARMS,
the method of choice in the clinic is immunohisto-
chemistry. Different myogenic marker proteins for RMS
in general (desmin) or for RMS subgroups (myogenin)
have been implemented in routine clinical diagnosis.
Nevertheless, subgroup specificity of these markers
leaves room for improvement.6 Additional potential
marker proteins for RMS subclassification have been
detected in gene expression profiling studies of RMS.7
Among them are epidermal growth factor receptor
(EGFR) and fibrillin-2 as markers for ERMS and AP2b
and P-cadherin as markers for translocation-positive
ARMS. We have recently evaluated these four markers
for their potential in aiding the subclassification of RMS
tumours using a RMS tissue microarray (TMA) and
found that they indeed allow immunohistochemical
subclassification of RMS with high specificity and
sensitivity.8
To validate these findings further for possible future
clinical implementation on a second, independent
patient cohort, we re-evaluated these markers on an
additional 80 RMS tumour specimens. Furthermore,
the suitability of the markers to distinguish ARMS from
tumours with potential similar clinical appearance,
especially lymphoma, was evaluated on a TMA repre-
senting 18 different non-RMS tumours.
Materials and methods
tumour specimens
Single sections (2 lm) of 80 paraffin-embedded RMS
specimens from patients diagnosed between 2001 and
2005 were obtained from the archives of the Depart-
ment of Pathology at the University of Kiel, Germany.
Histological classification was established locally and
by referral to the Cooperative Weichteilsarkom Studi-
engruppe (CWS). All tumours were histologically
subclassified as ARMS or ERMS.
Sections (2 lm) of a multi-tumour tissue array
containing cores of 175 tumours from 18 different
tissue origins and 38 cores from five different benign
tissue types were obtained from the Institute of Surgical
Pathology (University Hospital Zurich, Switzerland).
immunohistochemistry
Sections of both RMS tumours and the multi-tumour
TMA were immunohistochemically stained using the
Ventana Benchmark automated staining system (Ven-
tana Medical Systems, Tucson, AZ, USA) as described
previously.8 Briefly, slides were heated with either cell
conditioner 1 (for EGFR, AP2b and P-cadherin) or cell
conditioner 2 (fibrillin-2) and in some cases enzymat-
ically predigested with Ventana protease 1 for 4 min
(EGFR) or 8 min (fibrillin-2) to retrieve the antigens.
The sections were then incubated for 32 min with
primary antibodies against EGFR (clone 3C6, prediluted
by Ventana) or P-cadherin (clone 56, 1:50; BD
Transduction Labs, San Jose, CA, USA) or for 60 min
with antibodies against AP2b (H-87, purified rabbit
immunoglobulin fraction, 1:40; Santa Cruz Biotech-
nology, Santa Cruz, CA, USA) or fibrillin-2 (polyclonal
rabbit antibody, 1:200; Abcam plc, Cambridge, UK).
Visualization of the antibodies was performed with
either the Ventana iVIEW diaminobenzidene (DAB)
detection kit (for EGFR, AP2b and P-cadherin) or the
Ventana ultraVIEW DAB kit (for fibrillin-2). All tumour
tissues were counterstained with haematoxylin.
evaluation of immunohistochemical
reactivity
A scoring system based on three categories (0, 1 and 2)
was used to grade immunoreactivity. In cases without
any visible reactivity, the tumour was interpreted as
negative and classified as 0. Cases with weak or
moderate reactivity of a minority of cells were classified
as 1. Tumours with reactivity of the majority of cells or
heavy reactivity of a minority of cells were classified as
2. In order to rule out non specific background,
reactivity was interpreted as specific only when found
at the expected subcellular localization, i.e. at the cell
periphery (EGFR and P-cadherin), in the nucleus (AP2b)
or in the extracellular space (fibrillin-2). All sections
were evaluated independently by two investigators.
Sensitivity and specificity of the antibody markers
were calculated using the following formulae:
Sensitivity = number of true positives ⁄ (number of true
positives + number of false negatives).
Specificity = number of true negatives ⁄ (number of true
negatives + number of false positives).
Results
In a recent study, we investigated the potential of the
four biomarkers EGFR, fibrillin-2, AP2b and P-cadherin
for RMS subclassification by immunohistochemistry
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using a RMS TMA.8 There, high specificity and sensitiv-
ity could be demonstrated, confirming earlier gene
expression data. To validate these results on large single
tumour sections, for this study we used sections of a set of
80 independent RMS tumours from 78 paediatric
patients with a median age at diagnosis of 6.6 years.
According to histological classification, the study
group was composed of 59 ERMS and 21 ARMS
sections and included botryoid, pleomorphic and
anaplastic variants in the ERMS group as well as the
solid variant in the ARMS group (Table 1). All sections
of the RMS tumours were immunohistochemically
stained with antibodies against EGFR, AP2b, P-cadh-
erin and fibrillin-2. The antibodies against the first
three markers were the same as in our previous study,
whereas the anti-fibrillin-2 antibody was now
exchanged for a commercially available one. Immuno-
reactivity characteristics of the two anti-fibrillin-2
antibodies were very similar (data not shown). Repre-
sentative reactivity of all four markers in both a typical
ERMS and ARMS is shown in Figure 1. The frequency
of immunopositivity among the RMS subgroups was
determined and sensitivity and specificity were calcu-
lated (Table 2). Specific EGFR reactivity at the cell
periphery was found in 55 of 59 ERMS sections and in
6 of 21 ARMS sections. Specific fibrillin-2 reactivity in
the extracellular space was found in 56 of 59 ERMS
sections, but in only 6 of 22 ARMS. Double positivity of
these two markers was found in 53 of 59 ERMS but in
only 5 of 21 ARMS, resulting in a sensitivity of 90%
and specificity of 76% for the detection of ERMS.
Specific immunoreactivity of AP2b in the nucleus was
detected in 19 of 20 ARMS sections and in 3 of 59 ERMS
sections. Specific reactivity of P-cadherin at the cell
periphery was found in 19 of 20 ARMS sections and in 8
of 59 ERMS. Double positivity for these two markers was
found in 18 of 20 ARMS but only 2 of 59 ERMS, resulting
in a sensitivity of 90% and specificity of 97% for the
detection of ARMS with these two markers.
To evaluate the reproducibility of these results, we
compared sensitivity and specificity determined in
the present study with our previous TMA study
investigating the same four markers on 252 tumour
punches8 and with a second TMA study testing only
EGFR as a marker on 66 RMS tumours9 (Table 3). This
analysis revealed on the one hand that sensitivity of all
markers on single sections was significantly higher
than on TMAs. On the other hand, no major differences
regarding specificity were found among the different
studies.
The clinical presentation of ARMS can resemble
other tumour types. Especially in cases with an occult
primary tumour and widespread dissemination, ARMS
can mimic leukaemia or lymphoma. In such cases an
easy applicable diagnostic tool allowing discrimination
from other tumours is desirable. We therefore tested the
expression of our ARMS-specific markers AP2b and
P-cadherin in a range of non-RMS tumours by
immunohistochemistry of a TMA on which 18 different
malignant and five benign tissue types were repre-
sented. As summarized in Table 4, specific AP2b
reactivity was found in the majority of breast carcin-
omas (8 ⁄ 14) and melanomas (6 ⁄ 8). Furthermore, a
minority of the cases of bladder (2 ⁄ 8), lung (2 ⁄ 12),
ovarian (1 ⁄ 8), pancreatic (1 ⁄ 3) and skin (1 ⁄ 6) carcin-
omas were also AP2b positive. The remaining tumours,
including lymphoma and different non-RMS sarcomas,
were negative for AP2b. P-cadherin stained the
majority of both tumours and benign tissues repre-
sented on the multi-tumour microarray, but not
lymphomas, which were all clearly negative.
Discussion
Differences in treatment and prognosis among the
different RMS subgroups as well as potential misdiag-
nosis of ARMS due to resemblance to other tumour
types such as lymphoma underscore the importance of
developing diagnostic tools for RMS (sub)classification.
Gene expression profiling approaches carried out in
recent years have allowed the detection of a range of
Table 1. Tumour characteristics
Rhabdomyosarcoma* Patients (n)
ERMS 58
Botryoid 3 ⁄ 58
Pleomorphic 1 ⁄ 58
Anaplastic 4 ⁄ 58
Spindle cell 5 ⁄ 58
ARMS 20
Solid 7 ⁄ 20
Translocation positive† 8 ⁄ 20
Translocation negative 1 ⁄ 20
ERMS, embryonal rhabdomyosarcoma; ARMS, alveolar rhab-
domyosarcoma.
*All rhabdomyosarcoma tumours were immunopositive for
desmin and myogenin, except two that were not tested.
†Translocation status was determined by specific polymerase
chain reaction, but tested only in 11 ⁄ 20 ARMS. In addition,
eight ERMS tumours were tested and found negative for
PAX ⁄ FKHR translocations.
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Figure 1. Immunoreactivity of a typical embryonal rhabdomyosarcoma (right panel) and alveolar rhabdomyosarcoma (left panel) with
antibodies against AP2b, P-cadherin, epidermal growth factor receptor and fibrillin-2. Immunoreactivity was visualized with diaminobenzidene.
For grading system, see Materials and methods.
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potential biomarkers that might be suitable for RMS
subclassification. Some of these biomarkers, i.e. EGFR
and fibrillin-2 as ERMS-specific markers and AP2b and
P-cadherin as ARMS-specific markers, have indeed
been evaluated by immunohistochemistry on a RMS
TMA representing several hundred tumour specimens.8
The large number of samples that can be tested at once
make such a TMA an ideal tool for initial screening of
marker performance in terms of specificity and sensi-
tivity. Nevertheless, for future implementation in a
clinical setting, validation of the results with an
independent patient cohort and on full tumour sections
is indicated to exclude any potential bias due to the
limited size of the tumour specimens on the TMA.
Therefore, we validated the four markers on 80 single
RMS tumour sections from 78 patients. Compared with
Table 2. Summary of immunohistochemical data using four biomarkers
ERMS* ARMS*
Antibody Total Anaplastic Pleomorphic
Spindle
cell Botryoid Total Solid
Sensitivity
(%)
Specificity
(%)
EGFR 55 ⁄ 59 4 ⁄ 4 1 ⁄ 1 3 ⁄ 5 3 ⁄ 3 6 ⁄ 21 3 ⁄ 8 93.2 74.1
Fibrillin-2 56 ⁄ 59 4 ⁄ 4 1 ⁄ 1 4 ⁄ 5 3 ⁄ 3 5 ⁄ 21 2 ⁄ 8 94.9 76.1
EGFR + fibrillin-2 53 ⁄ 59 4 ⁄ 4 1 ⁄ 1 3 ⁄ 5 3 ⁄ 3 5 ⁄ 21 2 ⁄ 8 89.8 76.1
AP2b 3 ⁄ 59 0 ⁄ 4 0 ⁄ 1 0 ⁄ 5 0 ⁄ 3 19 ⁄ 20 7 ⁄ 7 95.0 94.9
P-cadherin 8 ⁄ 59 1 ⁄ 4 0 ⁄ 1 0 ⁄ 5 0 ⁄ 3 19 ⁄ 20 7 ⁄ 8 95.0 86.4
AP2b + P-cadherin 2 ⁄ 59 0 ⁄ 4 0 ⁄ 1 0 ⁄ 5 0 ⁄ 3 18 ⁄ 20 7 ⁄ 7 90.0 96.6
ERMS, embryonal rhabdomyosarcoma; ARMS, alveolar rhabdomyosarcoma; EGFR, epidermal growth factor receptor.
*Two patients were represented by two sections.
Table 3. Comparative immunohistochemical data
Antibody Study ERMS ARMS
Sensitivity
(%)
Specificity
(%)
EGFR Ganti et al.9 26 ⁄ 34 5 ⁄ 32 76 84
Wachtel et al.8 145 ⁄ 173 12 ⁄ 61 84 80
Present study 55 ⁄ 59 6 ⁄ 21 93 74
Fibrillin-2 Wachtel et al.8 120 ⁄ 176 7 ⁄ 59 68 88
Present study 56 ⁄ 59 5 ⁄ 21 95 76
EGFR + fibrillin-2 Wachtel et al.8 103 ⁄ 173 4 ⁄ 59 60 93
Present study 53 ⁄ 59 5 ⁄ 21 90 76
AP2b Wachtel et al.8 7 ⁄ 177 33 ⁄ 61 54 96
Present study 3 ⁄ 59 19 ⁄ 20 95 95
P-cadherin Wachtel et al.8 18 ⁄ 179 41 ⁄ 59 69 90
Present study 8 ⁄ 59 19 ⁄ 20 95 86
AP2b + P-cadherin Wachtel et al.8 0 ⁄ 176 32 ⁄ 59 54 100
Present study 2 ⁄ 59 18 ⁄ 20 90 97
ERMS, embryonal rhabdomyosarcoma; ARMS, alveolar rhabdomyosarcoma; EGFR, epidermal growth factor receptor.
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the tissue array data, sensitivity using full single
sections was higher for all four markers. This result is
not surprising, since in cases in which the tumour
tissue is not uniformly positive, positive areas may not
be represented on the TMA and staining may thus
result in false-negative samples. On the other hand, no
major difference in specificity between data from tissue
array and from whole sections was detected, demon-
strating that background reactivity of the antibodies
was comparable. Furthermore, data from a third study,
investigating EGFR expression in RMS subgroups, also
produced similar results for this marker.9
Table 4. Expression of
ARMS-specific biomarkers
in multiple tumour types
Tissue type AP2b P-cadherin
Malignant Total Positive Negative Positive Negative
Bladder 8 2 6 8 0
Brain 6 0 6 0 6
Breast 14 8 6 14 0
Colon 8 0 8 7 1
Kidney 10 0 10 5 5
Liver 5 0 5 3 2
Lung 12 2 10 12 0
Lymphoma 7 0 7 0 7
Melanoma 8 6 2 8 0
Ovary 8 1 7 8 0
Pancreas 3 1 2 4 0
Prostate 8 0 8 8 0
Sarcoma
2 Myxofibrosarcoma
2 Leiomyosarcoma
2 Synovial sarcoma
2 Undefined sarcoma
8 0 8 2 6
Seminoma 6 0 6 6 0
Skin 6 1 5 6 0
Teratoma 2 0 2 2 0
Thyroid 8 0 8 7 1
Uterus 7 0 7 7 0
Benign
Kidney 4 0 4 4 0
Liver 8 1 7 8 0
Pancreas 2 0 2 2 0
Placenta 8 0 8 8 0
Tonsil 15 3 12 8 7
ARMS, alveolar rhabdomyosarcoma.
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The ARMS-specific markers AP2b and P-cadherin
are expressed specifically in translocation-positive but
not -negative ARMS.8 However, the translocation
status is not known for all tumours in this study, and
this distinction was therefore not possible. Neverthe-
less, we found a high sensitivity of the two markers of
90% for the detection of ARMS. The remaining number
of negative ARMS cases of about 10% is very similar to
the number of true translocation-negative ARMS of
10–20% described in the literature.10 This suggests
that the sensitivity of our markers to detect transloca-
tion-positive ARMS is close to 100%. This is in line with
the finding that these markers are present within the
gene expression signature, which is a very specific and
consistent indication for the presence of PAX-translo-
cations in RMS,7,11,12 suggesting that these genes are
direct targets of the chimeric transcription factors
PAX3(or7) ⁄ FKHR. Supporting evidence for this
hypothesis has recently been obtained for AP2b.13
Based on this high specificity of these markers for the
detection of translocation-positive ARMS, it is reason-
able to speculate that the two ERMS found in this study
to be positive for both AP2b and P-cadherin also
represent translocation-positive ARMS, even if there
might be alternative translocations expressed.7,10
Due to its rapidly disseminating behaviour and the
nature of its cellular morphology, namely small round
blue cell tumours, ARMS can mimic the clinical
presentation of lymphoma or leukaemia in cases where
the primary tumour site is not detected. Testing 18
different non-RMS tumour types, we found that only
breast carcinomas and melanomas were immuno-
positive for AP2b in significant numbers. AP2b
alone therefore allows discrimination of ARMS from
different tumours, including those with potentially
similar appearance such as non-RMS sarcoma and
lymphoma. Combination with markers specific for
potentially similar tumours such as CD45 as a marker
for lymphomas14 could improve diagnosis further. On
the other hand, many different tumour types on the
array were positive for P-cadherin. This is not surpris-
ing, since most of the carcinomas are expected to
express junctional proteins such as cadherins, taking
their epithelial origin into account. More importantly,
however, seven out of seven lymphomas were also
negative for P-cadherin.
Taken together, our data suggest that the four
markers are suitable to make the clinically relevant
distinction between translocation-positive ARMS and
ERMS and allow further discrimination of transloca-
tion-positive ARMS from other tumours, especially
lymphoma. Therefore, these biomarkers represent
important tools for RMS diagnosis.
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